CoChat

Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials

Open access
van der Aart ‐ van der Beek, Annemarie B., van Raalte, Daniel H., Guja, Cristian, Hoogenberg, Klaas, Suchower, Lisa J., Hardy, Elise, Sjöström, C. David, Heerspink, Hiddo J.L. · 2020 · Diabetes, Obesity and Metabolism
Cited by 28

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Aims: To examine the albuminuria‐lowering effect of exenatide once weekly (EQW) compared with active glucose‐lowering comparators in patients with type 2 diabetes and elevated urinary albumin‐to‐creatinine ratio (uACR). Methods: Six randomized double‐blind and open‐label phase III studies were pooled in a post hoc , exploratory analysis to evaluate the efficacy and safety of EQW versus non‐glucagon‐like peptide‐1 receptor agonist comparators in patients with type 2 diabetes and baseline uACR ≥30 mg/g. Treatment groups were EQW versus all comparators pooled. Efficacy outcomes were percent change from baseline to week 26/28 in uACR and absolute change in glycated haemoglobin (HbA1c), systolic blood pressure (SBP), body weight and estimated glomerular filtration rate (eGFR). Results: Baseline characteristics were generally similar between the two treatment groups (EQW: N = 194, all comparators: N = 274). Relative to the comparator group, EQW changed albuminuria by −26.2% (95% confidence interval [CI] −39.5 to −10). Similar improvements were observed with EQW versus oral glucose‐lowering drugs (−29.6% [95% CI −47.6 to −5.3) or insulin (−23.8% [95% CI −41.8 to −0.2]). The effect of EQW on uACR was independent of baseline renin‐angiotensin system inhibitor usage. Adjusted mean decreases in HbA1c, SBP and body weight were more pronounced in the EQW versus the comparator group. Adjustment for changes in HbA1c, eGFR and SBP did not substantially affect the uACR‐lowering effect of EQW. When also adjusting for changes in body weight, the uACR‐lowering effect was reduced to (−13.0% [95% CI −29.9 to 7.8]). Conclusion: Exenatide once weekly reduced uACR in patients with type 2 diabetes and elevated albuminuria compared to commonly used glucose‐lowering drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.14067

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 16

  1. 10.2174/1573399812666151223093841 · DOI · Paper page
  2. 10.1016/S0140-6736(10)60590-9 · DOI · Paper page
  3. 10.2337/dc11-1107 · DOI · Paper page
  4. 10.1111/dom.12908 · DOI · Paper page
  5. 10.1016/j.clinthera.2012.07.007 · DOI
  6. 10.7326/0003-4819-130-6-199903160-00002 · DOI · Paper page
  7. 10.1053/j.ajkd.2008.12.034 · DOI · Paper page
  8. Perkovic V, 2019, FP482EGFR loss with glucagon‐like PEPTIDE‐1 (GLP‐1) analogue treatment: data from sustain 6 and leader, Nephrol Dial Transplant, 34
  9. 10.1016/S2213-8587(18)30104-9 · DOI · Paper page
  10. 10.1016/S2213-8587(16)30267-4 · DOI · Paper page
  11. 10.1056/NEJMoa1515920 · DOI · Paper page
  12. 10.1056/NEJMoa1611925 · DOI · Paper page
  13. 10.1136/bmj.k5301 · DOI · Paper page
  14. 10.7326/0003-4819-144-1-200601030-00006 · DOI · Paper page
  15. 10.1155/2012/608397 · DOI
  16. 10.1016/S2213-8587(19)30080-4 · DOI

Cited by

See all 28

Metadata

Authors
van der Aart ‐ van der Beek, A. B., van Raalte, D. H., Guja, C., Hoogenberg, K., Suchower, L. J., Hardy, E., Sjöström, C. D., & Heerspink, H. J. L.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2020-05-29
Volume
22
Issue
9
Pages
1556-1566
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W3018599559
Cited by
28
References
13
FWCI
2.87
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials. https://app.cochat.ai/papers/10.1111/dom.14067
The paper
van der Aart ‐ van der Beek, A. B., van Raalte, D. H., Guja, C., Hoogenberg, K., Suchower, L. J., Hardy, E., Sjöström, C. D., & Heerspink, H. J. L. (2020). Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14067

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.